Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Vonoprazan-amoxicillin dual therapy dose and duration study for Helicobacter pylori eradication
ChiCTR2300070603Phase 4Not yet recruiting
- Sponsor
- Fujian Provincial Hospital
- Start
- May 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of amoxicillin and vonoprazan in Helicobacter pylori infection (3 arms), sponsored by Fujian Provincial Hospital. Primary endpoint: Eradication rate. Planned start May 2023; status: not yet recruiting.
02
Drugs
amoxicillinvonoprazan
03
Conditions
Helicobacter pylori infection
Beyond the preview
Go deeper on ChiCTR2300070603.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2300070603.